Financial News
Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)
Price and Volume
Detailed Quote| Volume | 2,082,623 |
| Open | 122.19 |
| Bid (Size) | 119.59 (100) |
| Ask (Size) | 121.80 (400) |
| Prev. Close | 121.51 |
| Today's Range | 120.19 - 122.44 |
| 52wk Range | 61.23 - 122.44 |
| Shares Outstanding | 142,334,900 |
| Dividend Yield | N/A |
Top News
More News
Performance
52-Week Range
0.5% below 52-week high
121.84
61.2352W Low
122.4452W High
1 Week
0.5% below 1-week high
108.801W Low
122.441W High
Halozyme Therapeutics, Inc. - Common Stock (HALO) traded between $61.23 and $122.44 over the past 52 weeks and last traded at $121.84, 0.5% below its 52-week high. Over the past week it ranged between $108.80 and $122.44.
Past 12 Months
1W
+$10.76
1M
+$12.16
3M
+$44.75
6M
+$52.27
YTD
+$51.53
1Y
+$54.81
HALO was +81.8% over the past year, +75.1% over six months, +73.3% year to date, +9.7% in the last week.
12 Months vs Market
HALO
+81.8%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%
Over the past 12 months HALO returned +81.8% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.
Volume & Liquidity
0.93× 3-mo avg
Today 2,082,623
3-mo avg 2.2M
1W
2.4M
1M
2.9M
3M
2.2M
6M
2.0M
YTD
2.0M
1Y
2.0M
HALO most recently traded 2,082,623 shares against a 3-month average daily volume of 2.2M.
More News
Read More
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
September 24, 2026
1 Cash-Producing Stock to Target This Week and 2 We Question
September 22, 2026
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
August 31, 2026
3 Market-Beating Stocks for Long-Term Investors
August 28, 2026
1 Healthcare Stock with Exciting Potential and 2 We Avoid
August 27, 2026
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
August 24, 2026
Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
1 Profitable Stock to Research Further and 2 We Ignore
August 07, 2026
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
August 04, 2026
3 Growth Stocks Set to Flourish
August 03, 2026
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
July 24, 2026
1 Value Stock Worth Investigating and 2 Facing Headwinds
July 15, 2026
Frequently Asked Questions
Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 121.84
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 17.34B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 17B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
